Xarelto Lawsuits Consolidated In Louisiana MDL #Xarelto / #Xareltolawsuit / #Xareltomdl / #Xareltobleeding

Xarelto Bleeding Lawsuits have been consolidated in Louisiana Federal Court for Multidistrict Litigation. Plaintiffs in Xarelto bleeding lawsuits allege uncontrollable bleeding and other complications caused by the prescription blood thinner. Xarelto bleeding lawsuits will be consolidated in the U.S. District Court, Eastern District of Louisiana for coordinated pretrial proceedings,

Xarelto is an oral anticoagulant first approved by the U.S. Food and Drug Administration (FDA) in 2011. Xarelto is used to treat blood clots in the leg (deep vein thrombosis) and lungs (pulmonary embolism) and to reduce the risk of stroke and blood clots in patients with atrial fibrillation (irregular heart rhythms). Xarelto and Pradaxa are considered new generation blood thinners because prior to their approval, the FDA had only approved the one blood thinner warfarin (Coumadin, Jantoven) in the past 60 years. However, according to the FDA, unlike warfarin which has vitamin K as a reversal agent for bleeding, Xarelto does not have an antidote should severe bleeding occur in patients using the blood thinner.

Xarelto Cases

One Illinois complaint alleges a woman began taking the blood thinner medication in November 2013, and experienced uterine bleeding a few weeks later. The lawsuit alleges that the life-threatening episode caused the woman to be hospitalized and she had to receive multiple transfusions. The Xarelto bleeding side-effects complaint against Bayer and Janssen purports that the companies failed to adequately warn doctors and their patients about the bleeding risks associated with using Xarelto.

The U.S. Judicial Panel on Multidistrict Litigation (JPML) issued an order on Friday December 12, 2014 transferring 21 Xarelto lawsuits and over 30 potential tag-along actions pending in 22 federal courts to the Louisiana district court for coordination by Judge Eldon E. Fallon. The JPML’s order also stated that centralizing the cases will prevent inconsistent potential rulings and eliminate duplicative discovery. (In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592).

The JPML found that the Xarelto bleeding lawsuits share common questions of fact regarding the development, manufacturing and marketing of the blood thinner. The panel wrote the Xarelto complaints also had common allegations alleging defendants did not adequately warn doctors, patients and consumers about the severe or fatal bleeding risks associated with the blood thinner and there is no reversal agent available to counteract Xarelto’s anticoagulation effects.

The Ahearne Law Firm, PLLC offers free legal consultations nationwide for people who believe they have suffered serious side-effects after and uncontrolled bleeding caused by Xarelto.

Categories: